Joshua M. Zachariah - Partner

PDF Print Friendly Page
Joshua M. Zachariah

Download V-Card

San Francisco
Phone: +1 415-439-4310
Fax: +1 415-439-1500
Overview News Publications

Professional Profile

Joshua Zachariah’s practice focuses on mergers and acquisitions, corporate finance, securities and general corporate matters. He has represented public and private acquirers and target companies in a variety of domestic and cross-border acquisition and disposition transactions, joint ventures and other corporate transactions.

Representative Matters

  • Vista Equity Partners in its $4.3 billion acquisition of TIBCO Software;

  • Bristol-Myers Squibb in its $444 million (including milestones) acquisition of Galecto Biotech AB and $475 million (including milestones) acquisition of F-star Alpha Ltd.;

  • Vista Equity Partners in its $178 million acquisition of XRS Corporation;

  • Centerview as financial advisor to Activision Blizzard in its $8.2 billion repurchase of shares from Vivendi;

  • Bristol-Myers Squibb in its $4.3 billion sale to AstraZeneca of its interest in the companies’ diabetes alliance;

  • Citigroup as financial advisor to Ceradyne in its $860 million sale to 3M;

  • Akorn, Inc. in its $440 million acquisition of VPI Holdings Corp., the parent company of VersaPharm Incorporated;

  • Vista Equity Partners in its $644 million acquisition of Greenway Medical Technologies;

  • Akorn, Inc. in its $640 million acquisition of Hi-Tech Pharmacal; Vista Equity Partners in its $1.0 billion acquisition of Websense, Inc.;

  • Duff & Phelps Corporation in its $665 million acquisition by a private equity consortium led by The Carlyle Group;

  • Bristol-Myers Squibb in the $7 billion acquisition of Amylin Pharmaceuticals and joint collaboration with AstraZeneca plc;

  • Alcoa in its $27 billion proposed unsolicited acquisition of Alcan;

  • Realogy in its sale to Apollo for $9 billion;

  • Travelport in its sale to Blackstone for $4.3 billion;

  • Bristol-Myers Squibb in its $2.5 billion acquisition of Inhibitex;

  • Bristol-Myers Squibb in its $885 million acquisition of Zymogenetics;

  • Danaher in its $500 million acquisition of X-Rite;

  • Golden Gate Capital in its $470 million acquisition of California Pizza Kitchen;

  • Vestar Capital in its $294 million acquisition of Healthgrades;

  • ING in the sale of its $270 million reinsurance business;

  • Greenfield Partners in its $165 million acquisition of Clayton Holdings;

  • McCormick & Schmick’s Seafood Restaurants in connection with an unsolicited acquisition proposal from Landry’s;

  • McCormick & Schmick’s Seafood Restaurants in its sale to Landry’s for $131 million;

  • Caris Diagnostics in numerous acquisitions, including its $40 million acquisition of a molecular profiling company;

  • Healthsouth in a series of recapitalization transactions, including the company's $2 billion debt tender offer, $1 billion high-yield notes offering and $400 million private placement of preferred stock;

  • Cendant in its $2.6 billion debt tender offer;

  • Realogy in its $740 million self tender offer for common stock;

  • Cendant in its separation into four separate companies; and

  • Warnaco in various corporate matters, including the transfer of its listing to the NYSE and the sale of a division to an Italian apparel company.


Memberships & Affiliations

Member of the South Asian Bar Association of New York


Other Distinctions

Adjunct Professor, New York University School of Law, "Negotiating Corporate Transactions," 2013-2014

Prior Experience

Skadden, Arps, Slate, Meagher & Flom LLP, 2005-2010

© 2015 Kirkland & Ellis LLP